You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/Refractory Aggressive Mature B-cell Neoplasms

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Hodgkin Lymphoma Trial in Worldwide (Epcoritamab)

Recruiting
  • Non Hodgkin Lymphoma
  • Palo Alto, California
  • +44 more
Aug 12, 2022

Relapsed/Refractory Aggressive B-Cell Malignancies Trial (ONCT-808, Bridging Therapy)

Not yet recruiting
  • Relapsed/Refractory Aggressive B-Cell Malignancies
  • ONCT-808
  • Bridging Therapy
  • (no location specified)
Jan 19, 2023

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

    Not yet recruiting
    • Aggressive B-Cell Non-Hodgkin's Lymphoma
    • +4 more
    • (no location specified)
    Dec 16, 2022

    Mature B Cell Tumors Trial in Tianjin (SHR1459)

    Active, not recruiting
    • Mature B Cell Neoplasms
    • Tianjin, Tianjin, China
      Blood disease hospital of Chinese Academy of Medical Sciences
    Nov 10, 2022

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Spain (ARI0003)

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • ARI0003
    • Santiago De Compostela, A Coruña, Spain
    • +6 more
    Oct 24, 2023

    B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

    Not yet recruiting
    • B-cell Non-Hodgkins Lymphoma (B-NHL)
    • (no location specified)
    Jan 5, 2023

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

    Suspended
    • Recurrent Aggressive Non-Hodgkin Lymphoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 12, 2023

    B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

    Recruiting
    • B Cell Lymphoma
    • +5 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 3, 2023

    Refractory Leukemia, Relapsed Leukemia, Acute Myelogenous Leukemia Trial in Miami (STING-Dependent Activators (STAVs) Loaded

    Not yet recruiting
    • Refractory Leukemia
    • +4 more
    • STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells
    • Dendritic Cell Vaccine
    • Miami, Florida
      University of Miami
    Jan 23, 2023

    CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

    Not yet recruiting
    • CD19-positive Relapsed or Refractory B-cell Malignancies
    • UTAA09 cells for infusion
    • +2 more
    • Hefei, Anhui, China
      The First Affiliated Hospital of USTC (AnHui Provincial Hospital
    Oct 13, 2023

    Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

    Recruiting
    • Cutaneous T-Cell Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Relapsed/Refractory B-cell Malignancies Trial (AC676)

    Not yet recruiting
    • Relapsed/Refractory B-cell Malignancies
    • (no location specified)
    Mar 27, 2023

    Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Cologne, Germany
    • +1 more
    Mar 2, 2022

    Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

    Active, not recruiting
    • Relapsed or Refractory Diffuse Large B-cell Lymphoma
    • BEBT-908 for injection
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Oct 8, 2023

    Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

    Recruiting
    • Non-hodgkin Lymphoma
    • +2 more
    • CC312
    • Tianjin, Tianjin, China
      InstituteHBDH
    Sep 12, 2023

    Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 14, 2022

    Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • infusion of JY231 injection
    • Guangzhou, Guangdong, China
      Guangdong Second Provincial General Hospital
    Sep 17, 2023

    Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
    • (no location specified)
    Sep 5, 2023

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in United States (IMPT-314)

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Los Angeles, California
    • +3 more
    Apr 12, 2023